News

BASEL, December 19, 2022 – Mosanna Therapeutics, a preclinical-stage Biotech company focused on developing MOS-118, a pharmacologic therapy to treat obstructive sleep apnea (OSA), today announced that the CEO will participate in the Partnering Forum at the Biotech Showcase 2023 taking place in San Francisco, January 9-11, and virtually between January 17-18. Meeting schedules will be accessible to registered attendees. To schedule a meeting, please do so via the partneringONE platform.
Read More
BASEL, October 19, 2022 – Mosanna Therapeutics, a preclinical-stage Biotech company focused on developing MOS-118, a pharmacologic therapy to treat obstructive sleep apnea (OSA), today announced that the CEO will participate in the Partnering Forum at the BIO-EUROPE 2022 Conference taking place in Liepzig, Germany, October 24-26, and virtually between Nov 2-4, 2022. Meeting schedules will be accessible to registered conference attendees. To schedule a meeting, please do so via the partneringONE platform.
Read More
Company pursuing an advanced small molecule MOS-118 (formerly known as AVE0118) discovered by Sanofi. Experienced team with strong background in Metabolic Diseases and Obstructive Sleep Apnea. Seed financing led by Forty51 Ventures. Basel, Switzerland, July 13, 2022 /PRNewswire/ — Mosanna Therapeutics AG, a Swiss Biotech company today announced that it has secured seed financing led by Forty51 Ventures to pursue the development of AVE0118 which will be referred to as MOS-118 going forward, a small...
Read More